{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T05:35:25Z","timestamp":1776490525956,"version":"3.51.2"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:00:00Z","timestamp":1612915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:00:00Z","timestamp":1612915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1245\/s10434-021-09667-8","type":"journal-article","created":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T08:50:13Z","timestamp":1613033413000},"page":"2960-2972","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Rates, Predictors, and Outcomes of Portal Lymphadenectomy for Resectable Gallbladder Cancer"],"prefix":"10.1245","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1240-3889","authenticated-orcid":false,"given":"Phillip M.","family":"Kemp Bohan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne E.","family":"O\u2019Shea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oriana V.","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert C.","family":"Chick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex M.","family":"Clem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek T.","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia O.","family":"Bader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy E.","family":"Newhook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Travis","family":"Clifton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Wei D.","family":"Tzeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel W.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy J.","family":"Vreeland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,10]]},"reference":[{"key":"9667_CR1","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jss.2018.04.067","volume":"230","author":"AJ Lee","year":"2018","unstructured":"Lee AJ, Chiang YJ, Lee JE, et al. Validation of American Joint Committee on Cancer eighth staging system for gallbladder cancer and its lymphadenectomy guidelines. J Surg Res. 2018;230:148\u201354.","journal-title":"J Surg Res."},{"issue":"3","key":"9667_CR2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S1470-2045(03)01021-0","volume":"4","author":"S Misra","year":"2003","unstructured":"Misra S, Chaturvedi A, Misra NC, Sharma ID. Carcinoma of the gallbladder. Lancet Oncol. 2003;4(3):167\u201376.","journal-title":"Lancet Oncol."},{"key":"9667_CR3","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. National Comprehensive Cancer Network. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hepatobiliary.pdf. Published 2019. Updated 20 December 2019. Accessed 2020."},{"issue":"8","key":"9667_CR4","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/hpb.12444","volume":"17","author":"TA Aloia","year":"2015","unstructured":"Aloia TA, Jarufe N, Javle M, et al. Gallbladder cancer: expert consensus statement. HPB (Oxford). 2015;17(8):681\u201390.","journal-title":"HPB (Oxford)."},{"issue":"12","key":"9667_CR5","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1200\/JCO.18.02178","volume":"37","author":"RT Shroff","year":"2019","unstructured":"Shroff RT, Kennedy EB, Bachini M, et al. Adjuvant therapy for resected biliary tract cancer: ASCO Clinical practice guideline. J Clin Oncol. 2019;37(12):1015\u201327.","journal-title":"J Clin Oncol."},{"issue":"5","key":"9667_CR6","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663\u201373.","journal-title":"Lancet Oncol."},{"issue":"3","key":"9667_CR7","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/bjs.10776","volume":"105","author":"T Ebata","year":"2018","unstructured":"Ebata T, Hirano S, Konishi M, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018;105(3):192\u2013202.","journal-title":"Br J Surg."},{"issue":"8","key":"9667_CR8","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1200\/JCO.18.00050","volume":"37","author":"J Edeline","year":"2019","unstructured":"Edeline J, Benabdelghani M, Bertaut A, et al. Gemcitabine and Oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol. 2019;37(8):658\u201367.","journal-title":"J Clin Oncol."},{"issue":"24","key":"9667_CR9","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1200\/JCO.2014.60.2219","volume":"33","author":"E Ben-Josef","year":"2015","unstructured":"Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al. SWOG S0809: a Phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol. 2015;33(24):2617\u201322.","journal-title":"J Clin Oncol."},{"issue":"2","key":"9667_CR10","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1245\/s10434-018-7064-7","volume":"26","author":"E Vo","year":"2019","unstructured":"Vo E, Curley SA, Chai CY, Massarweh NN, Tran Cao HS. National failure of surgical staging for T1b gallbladder cancer. Ann Surg Oncol. 2019;26(2):604\u201310.","journal-title":"Ann Surg Oncol."},{"issue":"11","key":"9667_CR11","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.hpb.2018.05.007","volume":"20","author":"N Kohn","year":"2018","unstructured":"Kohn N, Maubach J, Warschkow R, et al. High rate of positive lymph nodes in T1a gallbladder cancer does not translate to decreased survival: a population-based, propensity score adjusted analysis. HPB (Oxford). 2018;20(11):1073\u201381.","journal-title":"HPB (Oxford)."},{"issue":"8","key":"9667_CR12","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1016\/j.ejso.2019.03.038","volume":"45","author":"K Toge","year":"2019","unstructured":"Toge K, Sakata J, Hirose Y, et al. Lymphatic spread of T2 gallbladder carcinoma: regional lymphadenectomy is required independent of tumor location. Eur J Surg Oncol. 2019;45(8):1446\u201352.","journal-title":"Eur J Surg Oncol."},{"issue":"4","key":"9667_CR13","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1097\/SLA.0000000000000728","volume":"261","author":"J Shindoh","year":"2015","unstructured":"Shindoh J, de Aretxabala X, Aloia TA, et al. Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: an international multicenter study. Ann Surg. 2015;261(4):733\u20139.","journal-title":"Ann Surg."},{"key":"9667_CR14","doi-asserted-by":"crossref","unstructured":"Pawlik TM, Gleisner AL, Vigano L, et al. Incidence of finding residual disease for incidental gallbladder carcinoma: implications for re-resection. J Gastrointest Surg. 2007;11(11):1478-1486; discussion 1486\u20131477.","DOI":"10.1007\/s11605-007-0309-6"},{"issue":"5","key":"9667_CR15","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1097\/00000658-199611000-00008","volume":"224","author":"DL Bartlett","year":"1996","unstructured":"Bartlett DL, Fong Y, Fortner JG, Brennan MF, Blumgart LH. Long-term results after resection for gallbladder cancer. Implications for staging and management. Ann Surg. 1996;224(5):639\u201346.","journal-title":"Ann Surg."},{"key":"9667_CR16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ijsu.2018.02.052","volume":"52","author":"JR Bergquist","year":"2018","unstructured":"Bergquist JR, Shah HN, Habermann EB, et al. Adjuvant systemic therapy after resection of node positive gallbladder cancer: Time for a well-designed trial? (Results of a US-national retrospective cohort study). Int J Surg. 2018;52:171\u20139.","journal-title":"Int J Surg."},{"key":"9667_CR17","doi-asserted-by":"publisher","unstructured":"Kemp Bohan PM, Kirby DT, Chick RC, et al. Adjuvant chemotherapy in resectable gallbladder cancer is underutilized despite benefits in node-positive patients. Ann Surg Oncol. 2020. https:\/\/doi.org\/10.1245\/s10434-020-08973-x.","DOI":"10.1245\/s10434-020-08973-x"},{"issue":"3","key":"9667_CR18","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/jso.25825","volume":"121","author":"K Sahara","year":"2020","unstructured":"Sahara K, Tsilimigras DI, Maithel SK, et al. Survival benefit of lymphadenectomy for gallbladder cancer based on the therapeutic index: an analysis of the US extrahepatic biliary malignancy consortium. J Surg Oncol. 2020;121(3):503\u201310.","journal-title":"J Surg Oncol."},{"key":"9667_CR19","doi-asserted-by":"publisher","first-page":"6961","DOI":"10.2147\/CMAR.S187857","volume":"10","author":"JY Lin","year":"2018","unstructured":"Lin JY, Bai DS, Zhou BH, et al. Positive relationship between number of negative lymph nodes and duration of gallbladder cancer cause-specific survival after surgery. Cancer Manag Res. 2018;10:6961\u20139.","journal-title":"Cancer Manag Res."},{"issue":"3","key":"9667_CR20","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1245\/s10434-007-9747-3","volume":"15","author":"KY Bilimoria","year":"2008","unstructured":"Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15(3):683\u201390.","journal-title":"Ann Surg Oncol."},{"issue":"5","key":"9667_CR21","first-page":"452","volume":"6","author":"TB Tran","year":"2015","unstructured":"Tran TB, Nissen NN. Surgery for gallbladder cancer in the US: a need for greater lymph node clearance. J Gastrointest Oncol. 2015;6(5):452\u20138.","journal-title":"J Gastrointest Oncol."},{"issue":"6","key":"9667_CR22","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s11605-011-1528-4","volume":"15","author":"SS Negi","year":"2011","unstructured":"Negi SS, Singh A, Chaudhary A. Lymph nodal involvement as prognostic factor in gallbladder cancer: location, count or ratio? J Gastrointest Surg. 2011;15(6):1017\u201325.","journal-title":"J Gastrointest Surg."},{"issue":"2","key":"9667_CR23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ejso.2015.10.013","volume":"42","author":"SH Kim","year":"2016","unstructured":"Kim SH, Chong JU, Lim JH, et al. Optimal assessment of lymph node status in gallbladder cancer. Eur J Surg Oncol. 2016;42(2):205\u201310.","journal-title":"Eur J Surg Oncol."},{"key":"9667_CR24","unstructured":"AJCC Cancer Staging Form Supplement. https:\/\/cancerstaging.org\/references-tools\/deskreferences\/Documents\/AJCC Cancer Staging Form Supplement.pdf. Published 2018. Accessed 13 March 2020, 2020."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-09667-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-021-09667-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-09667-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T14:11:23Z","timestamp":1620915083000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-021-09667-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,10]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["9667"],"URL":"https:\/\/doi.org\/10.1245\/s10434-021-09667-8","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,10]]},"assertion":[{"value":"25 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare. This research did not receive any specific grant from funding agenices in the public, commercial, or not-for-profit sectors. The results and opinions expressed in this article are those of the authors, and do not reflect the official policy or position of the US Army Medical Department, Department of the Army, Department of Defense, or the US Government.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}